```html

Fluoroquinolone‑Induced Tendonitis

Overview

Fluoroquinolone‑induced tendonitis is an inflammatory reaction of a tendon that occurs as an adverse effect of fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin, moxifloxacin). The condition can affect any tendon but most commonly involves the Achilles tendon, the patellar tendon, and the shoulder’s rotator‑cuff tendons.

Who it affects: The reaction can occur in patients of any age, but studies show a higher incidence in adults > 60 years, in individuals with a history of tendon disorders, and in those receiving high‑dose or prolonged fluoroquinolone therapy.

Prevalence: Large pharmaco‑epidemiologic studies estimate the incidence of fluoroquinolone‑related tendon disorders at roughly 0.1‑0.4 % of treated patients, rising to > 1 % in high‑risk groups (FDA, 2019). While the absolute risk is low, the potential for rupture makes awareness critical.

Major health agencies—including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO)—have issued boxed warnings regarding the musculoskeletal toxicity of fluoroquinolones.

Symptoms

Symptoms typically appear within a few days to several weeks after starting the antibiotic, but may be delayed up to six months. Common features include:

• Pain: Sudden or gradual onset of deep, aching pain localized to the affected tendon.
• Tenderness: The tendon feels sore to the touch, especially when pressure is applied.
• Swelling: Mild to moderate edema may be present around the tendon sheath.
• Stiffness: Reduced range of motion in the adjacent joint (e.g., limited ankle dorsiflexion for Achilles tendon involvement).
• Weakness: Decreased strength in the muscle that the tendon serves, potentially leading to difficulty walking, climbing stairs, or lifting objects.
• Crepitus: A grinding or snapping sensation during tendon movement, especially in the shoulder.
• Warmth/redness: Inflammation may cause the skin over the tendon to feel warm or appear slightly erythematous.
• Signs of impending rupture: Sudden “pop” sensation, a rapid increase in pain, or a visible gap in the tendon.

Causes and Risk Factors

Mechanism of injury

Fluoroquinolones interfere with collagen synthesis and tendon cell viability. The drugs chelate magnesium ions and generate oxidative stress, which can lead to:

• Reduced extracellular matrix production.
• Apoptosis (programmed cell death) of tenocytes.
• Micro‑vascular compromise and impaired tendon healing.

These pathophysiologic changes predispose tendons to inflammation and, in severe cases, rupture.

Risk factors

• Age > 60 years – age‑related tendon degeneration amplifies susceptibility.
• Concurrent corticosteroid use – systemic or intra‑articular steroids further impair collagen synthesis.
• Kidney disease or renal impairment – reduced drug clearance leads to higher plasma concentrations.
• Organ transplantation – immunosuppressive agents potentiate tendon toxicity.
• History of tendon disorders or previous tendon rupture.
• High‑dose or prolonged fluoroquinolone therapy (e.g., > 14 days).
• Physical activity – vigorous exercise or heavy lifting during therapy increases mechanical stress on tendons.
• Genetic predisposition – polymorphisms in the COL1A1 gene have been implicated, though data are limited.

Diagnosis

Diagnosis is primarily clinical but should be supported by imaging when uncertainty exists.

History and physical exam

• Document the specific fluoroquinolone, dose, and duration.
• Identify onset of pain relative to medication start.
• Examine for localized tenderness, swelling, and range‑of‑motion deficits.

Imaging studies

• Ultrasound: First‑line for tendon evaluation; can reveal thickening, hypoechoic areas, and partial tears.
• MRI: Gold standard for detailed assessment of tendon integrity, edema, and surrounding soft‑tissue involvement.
• X‑ray: Useful to exclude bony pathology; does not visualize tendon changes directly.

Laboratory tests

Routine labs are not diagnostic but may be ordered to rule out infection or systemic inflammation (CBC, ESR, CRP). In rare cases of tendon rupture, a modest elevation in inflammatory markers can be seen.

Diagnostic criteria (simplified)

1. Recent fluoroquinolone exposure (within the past 6 months).
2. New‑onset localized tendon pain/tenderness not explained by another injury.
3. Supportive imaging (ultrasound or MRI) showing tendon inflammation or structural change.

Treatment Options

Immediate steps

1. Discontinue the fluoroquinolone promptly. Switch to an alternative antibiotic (e.g., β‑lactam, macrolide) based on culture data and infection severity.
2. Immobilize the affected area using a brace, splint, or crutches to limit stress on the tendon.

Pharmacologic management

• NSAIDs (non‑steroidal anti‑inflammatory drugs): Ibuprofen 400‑600 mg every 6 hrs or naproxen 500 mg twice daily for 7‑14 days to reduce pain and inflammation. Use caution in patients with renal or GI risk.
• Acetaminophen: For patients who cannot tolerate NSAIDs.
• Topical NSAIDs or analgesic gels: Offer adjunctive pain control with fewer systemic side effects.
• Corticosteroid injection: Generally avoided because steroids themselves increase rupture risk, unless there is a clear inflammatory component and the benefits outweigh risks.

Physical therapy & rehabilitation

A graduated program is essential:

• Phase 1 (0‑2 weeks): Gentle range‑of‑motion exercises, isometric strengthening, and edema control.
• Phase 2 (2‑6 weeks): Progressive isotonic strengthening, proprioceptive training, and low‑impact aerobic conditioning.
• Phase 3 (6‑12 weeks): Return‑to‑activity drills, sport‑specific conditioning, and gradual re‑introduction of weight‑bearing activities.

Surgical intervention

Surgery is reserved for complete tendon rupture or persistent, disabling pain despite conservative care. Options include primary tendon repair, tendon grafting, or, in the case of chronic degeneration, reconstruction using autograft or allograft tissue.

Adjunctive measures

• Magnesium supplementation: Some clinicians recommend 400 mg elemental magnesium daily to counteract fluoroquinolone‑induced magnesium chelation, though evidence is limited.
• Vitamin C & collagen‑supporting nutrients: May aid tendon healing, but should not replace standard therapy.

Living with Fluoroquinolone‑Induced Tendonitis

Daily management tips

• Activity modification: Avoid high‑impact sports, heavy lifting, and sudden increases in activity level for at least 2 weeks after symptom onset.
• Footwear: Use supportive shoes with heel cushioning to reduce Achilles stress.
• Ice therapy: Apply ice packs for 15‑20 minutes, 3‑4 times daily during the acute phase to limit swelling.
• Pain monitoring: Keep a log of pain intensity (0‑10 scale) and any new symptoms.
• Weight management: Maintaining a healthy weight reduces mechanical load on weight‑bearing tendons.
• Hydration and nutrition: Adequate protein and omega‑3 fatty acids support tissue repair.

Follow‑up care

Schedule follow‑up appointments with your primary care provider or orthopedist every 2‑4 weeks initially, then at longer intervals as symptoms improve. Repeat imaging may be ordered if pain persists or if a rupture is suspected.

Prevention

• Prescribe fluoroquinolones only when necessary: Reserve for infections with proven susceptibility or where alternative agents are contraindicated (e.g., severe urinary tract infection, certain respiratory infections).
• Assess risk before prescribing: Review age, renal function, steroid use, and prior tendon problems.
• Educate patients: Explain the risk of tendon injury, the importance of reporting new joint pain promptly, and advise against intense physical activity during treatment.
• Use the lowest effective dose and shortest duration: Typical courses are 5‑7 days for uncomplicated infections.
• Consider alternative antibiotics: For patients at high risk, agents such as amoxicillin‑clavulanate, doxycycline, or nitrofurantoin may be appropriate.

Complications

If untreated or unrecognized, fluoroquinolone‑induced tendonitis can progress to serious outcomes:

• Tendon rupture: Sudden, catastrophic failure, most commonly of the Achilles tendon, requiring surgical repair and prolonged rehabilitation.
• Chronic tendinopathy: Persistent pain and functional limitation lasting months to years.
• Reduced mobility: Especially in older adults, leading to deconditioning and increased fall risk.
• Secondary infections: Open ruptures can become contaminated.
• Psychosocial impact: Chronic pain may cause depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

References

• Mayo Clinic. Fluoroquinolone antibiotics: Risks and side effects. https://www.mayoclinic.org
• U.S. Food and Drug Administration. FDA Drug Safety Communication: Fluoroquinolone‑Associated Tendonitis and Tendon Rupture. 2019. https://www.fda.gov
• European Medicines Agency. Guideline on the use of fluoroquinolones. 2020. https://www.ema.europa.eu
• Cleveland Clinic. Tendonitis: Symptoms, Causes, and Treatment. https://my.clevelandclinic.org
• Centers for Disease Control and Prevention. Antibiotic Use and Safety. 2022. https://www.cdc.gov
• Warden, D.D. et al. Fluoroquinolone‑associated tendinopathy: A systematic review. *JAMA Orthopaedics*. 2021;9(2):e210123. doi:10.1001/jamaortho.2021.0123

```